Abstracts tagged "registry and rheumatoid arthritis (RA)"

Abstract Number: 418 • 2014 ACR/ARHP Annual Meeting
Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis Patients
Vibeke Strand¹, Robert J. Holt², Katherine C. Saunders³, Jeffery D. Kent⁴, Ping Xu⁵, Amy Y. Grahn⁴, Marc Mason³ and Carol J. Etzel^6,7, ¹Stanford University, Palo Alto, CA, ²University of Illinois - Chicago, Chicago, IL, ³Corrona, LLC., Southborough, MA, ⁴Horizon Pharma, Inc., Deerfield, IL, ⁵Axio Research LLC, Seattle, WA, ⁶PO Box 786, Corrona, LLC., Southborough, MA, ⁷Department of Epidemiology, UT MD Anderson, Houston, TX
Background/Purpose : Morning stiffness is a symptom of rheumatoid arthritis (RA) that is frequently reported and thought to reflect disease activity, but its etiology is…
Abstract Number: 2813 • 2014 ACR/ARHP Annual Meeting
Correlation of Morning Stiffness with Measures of Higher Disease Activity in a Large US Registry Population of Rheumatoid Arthritis Patients
Vibeke Strand¹, Robert J. Holt², Katherine C. Saunders³, Jeffery D. Kent⁴, Ping Xu⁵, Amy Y. Grahn⁴, Marc Mason³ and Carol J. Etzel^6,7, ¹Stanford University, Palo Alto, CA, ²University of Illinois - Chicago, Chicago, IL, ³Corrona, LLC., Southborough, MA, ⁴Horizon Pharma, Inc., Deerfield, IL, ⁵Axio Research LLC, Seattle, WA, ⁶PO Box 786, Corrona, LLC., Southborough, MA, ⁷Department of Epidemiology, UT MD Anderson, Houston, TX
Background/Purpose : Morning stiffness may not be specifically queried by rheumatologists in the course of their regular interactions with rheumatoid arthritis (RA) patients. This analysis…
Abstract Number: 2562 • 2014 ACR/ARHP Annual Meeting
The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis and ankylosing spondylitis; results from Turkbio Registry
Ismail Sari¹, Umut Kalyoncu², Ahmet Mesut Onat³, Omer Nuri Pamuk⁴, Omer Karadag², Bunyamin Kisacik³, Niels Steen Krogh⁵, Soner Şenel⁶, Fatih Saritaş⁷, Ihsan Ertenli², Sedat Kiraz², Pinar Cetin¹, Fatos Onen¹ and Nurullah Akkoc¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, ³Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁴Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, ⁵Consultant, ZiteLab Aps, Copenhagen, Denmark, ⁶Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, ⁷Rheumatology, Trakya University School of Medicine, Edirne, Turkey
Background/Purpose Three different anti–tumor necrosis factor α (anti-TNFα) drugs (infliximab, etanercept, and adalimumab) are approved for patients with rheumatoid arthritis (RA) and particular ankylosing spondylitis…
Abstract Number: 2504 • 2014 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients
Nobunori Takahashi¹, Toshihisa Kojima¹, Yuji Hirano², Yasuhide Kanayama³, Koji Funahashi⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose Abatacept (ABT), a selective co-stimulation modulator, is the first in a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].